Memory-Like CAR-NK Cells Targeting NPM1c for Safer Tumor Killing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CAR-T therapies targeting lineage-restricted or tumor-associated antigens face severe toxicity due to low antigen expression in normal tissues and develop tumor resistance due to loss of TAA expression, necessitating more effective strategies for enhancing persistence, in vivo expansion, and effector functions of NK cells.
Innovation Solution
Development of engineered cytokine-induced memory-like NK cells expressing a chimeric antigen receptor (CAR) that specifically binds to the NPM1c neoepitope in complex with MHC class I protein, minimizing off-target binding and enhancing NK cell activation and tumor targeting.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional CAR T-cell therapy is used, then cancer treatment efficacy is achieved, but manufacturing complexity and cost are high
Solution Approach 1:
The patent segments the complex CAR T-cell manufacturing process into distinct modular steps: (1) generating memory-like NK cells with basic functions, (2) introducing specific receptor components (CD19, CD20, etc.) through transduction, and (3) optimizing cytokine production. This segmentation allows each step to be optimized independently and simplifies the overall manufacturing pipeline compared to conventional single-step CAR T-cell generation.
Solution Approach 2:
The patent introduces memory-like NK cells as an intermediary cell type that serves as a platform for delivering cancer-fighting functions. These NK cells are engineered to express both cytokines and specific receptors, acting as a mediator between the patient's immune system and the cancer target, thereby simplifying the therapeutic approach compared to conventional direct CAR T-cell therapy.
2Reliability
If conventional CAR T-cell therapy is used, then cancer treatment efficacy is achieved, but production time and cost are extended
Solution Approach 1:
The patent performs preliminary actions by pre-engineering memory-like NK cells with cytokine production capabilities and specific receptor expression before the actual therapy administration. This preliminary preparation of the cell platform reduces the time required during the critical therapy production phase, as the cells are already primed for their intended function.
Solution Approach 2:
The patent changes key parameters of the NK cell population, including cytokine expression levels, receptor specificity, and cell activation states, to optimize both efficacy and production efficiency. By adjusting these parameters, the patent achieves comparable or superior cancer treatment efficacy with reduced production time and lower costs compared to conventional CAR T-cell therapy.
3Reliability
If engineered memory-like NK cells are generated, then treatment specificity and efficacy are improved, but cell generation complexity increases
Solution Approach 1:
The patent applies local quality by introducing specific receptor components (such as CD19, CD20, or other tumor-specific antigens) only to the NK cell population that requires tumor specificity, while maintaining the general memory-like NK cell population with cytokine production capabilities. This localized modification approach maintains treatment specificity without unnecessarily complicating the entire cell generation process.
Data Source
Figure 1
Figure 2A~2B
Figure 2C
AI summary
The present disclosure relates to cytokine-induced memory-like NK cells expressing a chimeric antigen receptor polypeptide that binds to a neoepitope of mutant nucleophosmin (NPM1c) in complex with, or presented by, a class I major histocompatibility complex (MHC class I) protein, or cells expressing such compounds, and their use in methods for treating, or ameliorating one or more symptoms of, cancer.